vibostolimab + pembrolizumab + lenvatinib

This is a pharmaceutical **combination therapy** consisting of three individual drugs: **vibostolimab** (an anti-TIGIT monoclonal antibody, developed as MK-7684 or MK-7684A), **pembrolizumab** (a PD-1 immune checkpoint inhibitor, marketed as Keytruda), and **lenvatinib** (a multi-kinase inhibitor targeting VEGFR, FGFR, PDGFRα, RET, and KIT). - *Vibostolimab* blocks TIGIT, a checkpoint that inhibits T-cell activation, aiming to enhance anti-tumor immunity. - *Pembrolizumab* blocks PD-1 on T cells, releasing immune checkpoint inhibition and boosting immune-mediated tumor cell killing. - *Lenvatinib* is a small molecule that inhibits several receptor tyrosine kinases involved in angiogenesis and tumor proliferation, notably VEGFR, FGFR, and others. This triple combination is under clinical investigation, particularly for advanced solid tumors (e.g., non-small cell lung cancer, endometrial cancer), with studies focusing on synergistic immune activation and inhibition of tumor growth/angiogenesis. The combination is not yet FDA approved or marketed under a brand name but is in various clinical trial stages for oncology indications.

Other names

vibostolimab + pembrolizumab + lenvatinibMK-7684 + pembrolizumab + lenvatinibMK-7684A + pembrolizumab + lenvatinib